UPMC Univ Paris 06, INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe: épidémiologie hospitalière qualité et organisation des soins, Medical Intensive Care, Sorbonne Universités, 184 rue du Faubourg Saint Antoine, 75012, Paris, France.
Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, service de réanimation médicale, 75012, Paris, France.
Intensive Care Med. 2022 Apr;48(4):435-447. doi: 10.1007/s00134-022-06642-z. Epub 2022 Feb 26.
The number of patients ≥ 80 years admitted into critical care is increasing. Coronavirus disease 2019 (COVID-19) added another challenge for clinical decisions for both admission and limitation of life-sustaining treatments (LLST). We aimed to compare the characteristics and mortality of very old critically ill patients with or without COVID-19 with a focus on LLST.
Patients 80 years or older with acute respiratory failure were recruited from the VIP2 and COVIP studies. Baseline patient characteristics, interventions in intensive care unit (ICU) and outcomes (30-day survival) were recorded. COVID patients were matched to non-COVID patients based on the following factors: age (± 2 years), Sequential Organ Failure Assessment (SOFA) score (± 2 points), clinical frailty scale (± 1 point), gender and region on a 1:2 ratio. Specific ICU procedures and LLST were compared between the cohorts by means of cumulative incidence curves taking into account the competing risk of discharge and death.
693 COVID patients were compared to 1393 non-COVID patients. COVID patients were younger, less frail, less severely ill with lower SOFA score, but were treated more often with invasive mechanical ventilation (MV) and had a lower 30-day survival. 404 COVID patients could be matched to 666 non-COVID patients. For COVID patients, withholding and withdrawing of LST were more frequent than for non-COVID and the 30-day survival was almost half compared to non-COVID patients.
Very old COVID patients have a different trajectory than non-COVID patients. Whether this finding is due to a decision policy with more active treatment limitation or to an inherent higher risk of death due to COVID-19 is unclear.
入住重症监护病房的 80 岁以上患者人数不断增加。2019 年冠状病毒病(COVID-19)给临床决策带来了新的挑战,包括收治和限制生命支持治疗(LLST)。我们旨在比较有无 COVID-19 的非常高龄危重症患者的特征和死亡率,并重点关注 LLST。
从 VIP2 和 COVIP 研究中招募了急性呼吸衰竭且年龄≥80 岁的患者。记录了患者的基线特征、重症监护病房(ICU)中的干预措施和结局(30 天生存率)。根据年龄(±2 岁)、序贯器官衰竭评估(SOFA)评分(±2 分)、临床虚弱量表(±1 分)、性别和地区,将 COVID 患者与非 COVID 患者进行 1:2 匹配。通过考虑出院和死亡的竞争风险,使用累积发病率曲线比较了两组 ICU 特定程序和 LLST。
共比较了 693 例 COVID 患者和 1393 例非 COVID 患者。COVID 患者年龄较小,虚弱程度较低,SOFA 评分较低,病情较轻,但更常接受有创机械通气(MV)治疗,30 天生存率较低。404 例 COVID 患者可与 666 例非 COVID 患者匹配。与非 COVID 患者相比,COVID 患者的 LLST 暂停和停止更为频繁,30 天生存率几乎为非 COVID 患者的一半。
非常高龄的 COVID 患者与非 COVID 患者的轨迹不同。这种发现是由于更积极的治疗限制决策策略所致,还是由于 COVID-19 本身导致的死亡风险更高所致尚不清楚。